Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
All-trans retinoic acid-based treatment for adenoid cystic carcinoma with lung metastasis risk stratification
ChiCTR2200060778Phase 4Not yet recruiting
- Sponsor
- Beijing Tongren Hospital
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of tretinoin in adenoid cystic carcinoma (ACC) (2 arms), sponsored by Beijing Tongren Hospital. Primary endpoints: Distant metastasis-free survival and Objective response rate. Planned start Jan 2022; status: not yet recruiting.
02
Drugs
tretinoin
03
Conditions
adenoid cystic carcinoma (ACC)
Beyond the preview
Go deeper on ChiCTR2200060778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060778.